National Account Director, Enterprise Access
Full-time
US
Oct 21, 2026
RemoteMatch analyzes your experience against this role's specific tech stack, timezone overlap, and requirements.
About the Role
Company Overview Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been accepted by the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-1617, a clinical-stage solid tumor ADC; and IM-3050, a clinical-stage FAP-targeted radioligand therapy. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. Position Overview Immunome is seeking a highly experienced and strategic National Account Director, Enterprise Access to lead integrated account strategy across a U.S. national footprint in support of our oncology portfolio. This role will build and sustain relationships with national and regional health plans, pharmacy benefit managers (PBMs), and Key Account customer networks to advance launch readiness, appropriate coverage and reimbursement, formulary access, and therapeutic adoption following regulatory approval. The successful candidate will bring deep expertise in payer access and institutional purchasing, recognizing the distinct operating models, decision processes, and account economics of each. This position combines direc